Literature DB >> 27020089

Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma.

Nikoletta Lendvai1, Andrew J Yee2, Ioanna Tsakos3, Aeri Alexander3, Sean M Devlin4, Hani Hassoun1, Neha Korde1, Alexander M Lesokhin1, Heather Landau5, Sham Mailankody1, Guenther Koehne5, David J Chung5, Ola Landgren1, Noopur S Raje2, Sergio Giralt5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27020089      PMCID： PMC5003505          DOI： 10.1182/blood-2016-01-694786

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  11 in total

1.  Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.

Authors:  F Michael Yakes; Jason Chen; Jenny Tan; Kyoko Yamaguchi; Yongchang Shi; Peiwen Yu; Fawn Qian; Felix Chu; Frauke Bentzien; Belinda Cancilla; Jessica Orf; Andrew You; A Douglas Laird; Stefan Engst; Lillian Lee; Justin Lesch; Yu-Chien Chou; Alison H Joly
Journal:  Mol Cancer Ther       Date:  2011-09-16       Impact factor: 6.261

2.  Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy.

Authors:  Carina Seidel; Stig Lenhoff; Sigmund Brabrand; Gøran Anderson; Therese Standal; Johan Lanng-Nielsen; Ingemar Turesson; Magne Børset; Anders Waage
Journal:  Br J Haematol       Date:  2002-12       Impact factor: 6.998

3.  Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group.

Authors:  C Seidel; M Børset; I Turesson; N Abildgaard; A Sundan; A Waage
Journal:  Blood       Date:  1998-02-01       Impact factor: 22.113

4.  Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response.

Authors:  Ludek Pour; Hana Svachova; Zdenek Adam; Martina Almasi; Lucie Buresova; Tomas Buchler; Lucie Kovarova; Pavel Nemec; Miroslav Penka; Jiri Vorlicek; Roman Hajek
Journal:  Ann Hematol       Date:  2009-09-26       Impact factor: 3.673

5.  PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.

Authors:  Yong Choi; Jie Zhang; Cristina Murga; Hong Yu; Erich Koller; Brett P Monia; J Silvio Gutkind; Weiqun Li
Journal:  Oncogene       Date:  2002-08-08       Impact factor: 9.867

6.  A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.

Authors:  Håkon Hov; Randi Utne Holt; Torstein Baade Rø; Unn-Merete Fagerli; Henrik Hjorth-Hansen; Vadim Baykov; James G Christensen; Anders Waage; Anders Sundan; Magne Børset
Journal:  Clin Cancer Res       Date:  2004-10-01       Impact factor: 12.531

7.  Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator.

Authors:  Esther P M Tjin; Patrick W B Derksen; Hiroaki Kataoka; Marcel Spaargaren; Steven T Pals
Journal:  Blood       Date:  2004-06-01       Impact factor: 22.113

8.  Pretreatment hepatocyte growth factor and thrombospondin-1 levels predict response to high-dose chemotherapy for multiple myeloma.

Authors:  L Pour; H Svachova; Z Adam; Z Mikulkova; L Buresova; L Kovarova; T Buchler; M Penka; J Vorlicek; R Hajek
Journal:  Neoplasma       Date:  2010       Impact factor: 2.575

9.  Targeting MET transcription as a therapeutic strategy in multiple myeloma.

Authors:  Cornel J Phillip; Christine M Stellrecht; Ramadevi Nimmanapalli; Varsha Gandhi
Journal:  Cancer Chemother Pharmacol       Date:  2008-05-29       Impact factor: 3.333

10.  Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myeloma.

Authors:  K F Wader; U M Fagerli; R U Holt; B Stordal; M Børset; A Sundan; A Waage
Journal:  Eur J Haematol       Date:  2008-08-06       Impact factor: 2.997
View more
  5 in total

Review 1.  Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma.

Authors:  Manuela Schmidinger; Romano Danesi
Journal:  Oncologist       Date:  2017-11-16

2.  Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.

Authors:  Muhamed Baljevic; Shadia Zaman; Veerabhadran Baladandayuthapani; Yan Heather Lin; Claudia Morales de Partovi; Zuzana Berkova; Behrang Amini; Sheeba K Thomas; Jatin J Shah; Donna M Weber; Min Fu; Charles S Cleeland; Xin Shelley Wang; Christine M Stellrecht; Richard E Davis; Varsha Gandhi; Robert Z Orlowski
Journal:  Ann Hematol       Date:  2017-03-23       Impact factor: 3.673

Review 3.  AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma.

Authors:  Siyang Yan; Niels Vandewalle; Nathan De Beule; Sylvia Faict; Ken Maes; Elke De Bruyne; Eline Menu; Karin Vanderkerken; Kim De Veirman
Journal:  Cancers (Basel)       Date:  2019-11-05       Impact factor: 6.639

4.  Therapeutic outcome of early-phase clinical trials in multiple myeloma: a meta-analysis.

Authors:  Niels van Nieuwenhuijzen; Rowan Frunt; Anne M May; Monique C Minnema
Journal:  Blood Cancer J       Date:  2021-03-01       Impact factor: 11.037

Review 5.  The HGF/c-MET axis as a potential target to overcome survival signals and improve therapeutic efficacy in multiple myeloma.

Authors:  Paolo Giannoni; Daniela de Totero
Journal:  Cancer Drug Resist       Date:  2021-10-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.